Neuronetics to Present at the 30th Annual Piper Jaffray Healthcare Conference

MALVERN, Pa., Nov. 15, 2018 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that Chris Thatcher, President and Chief Executive Officer, and Peter Donato, Chief Financial Officer, will participate in the 30th Annual Piper Jaffray Healthcare Conference at in New York, NY on Wednesday, November 28, 2018. The Company is scheduled to present at the conference at 2:30 PM Eastern Time the same day.

A live audio webcast of the conference presentation will be available online at the investor relations page of the Company’s website at www.neuronetics.com. A replay of the webcast will be archived on the website for approximately 90 days.

About NeuroneticsNeuronetics, Inc. is a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar® Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood.  The system is cleared by the United States Food and Drug Administration, or FDA. NeuroStar Advanced TMS Therapy is indicated for the treatment of major depressive disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode.  Additional information can be found at www.neuronetics.com.

Investor Contact:Mark R. Klausner Westwicke Partners  443-213-0501 [email protected] 

Media Contact:Leanne Scott Brown  Vault Communications 610-455-2742 [email protected] 

You May Also Be Interested In

• FDA accepts Teva's drug application for Tourette syndrome therapy in children
• Dimensional Fund Advisors Ltd. : Form 8.3 - GAMMA COMMUNICATIONS PLC - Ordinary Shares
• Dimensional Fund Advisors Ltd. : Form 8.3 - PROLOGIS INC - Ordinary Shares